A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

Abstract Background We previously showed that the bacterial lipopeptide Pam3Cys-Ser-Ser, meanwhile established as a toll-like receptor (TLR) 1/2 ligand, acts as a strong adjuvant for the induction of virus specific CD8+ T cells in mice, when covalently coupled to a synthetic peptide. Case presentati...

Full description

Bibliographic Details
Main Authors: Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Anoop Chandran, Henning Zelba, Elisa Rusch, Cécile Gouttefangeas, Daniel J. Kowalewski, Moreno Di Marco, Sebastian P. Haen, Juliane S. Walz, Yamel Cardona Gloria, Johanna Bödder, Jill-Marie Schertel, Antje Tunger, Luise Müller, Maximilian Kießler, Rebekka Wehner, Marc Schmitz, Meike Jakobi, Nicole Schneiderhan-Marra, Reinhild Klein, Karoline Laske, Kerstin Artzner, Linus Backert, Heiko Schuster, Johannes Schwenck, Alexander N. R. Weber, Bernd J. Pichler, Manfred Kneilling, Christian la Fougère, Stephan Forchhammer, Gisela Metzler, Jürgen Bauer, Benjamin Weide, Wilfried Schippert, Stefan Stevanović, Markus W. Löffler
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Adjuvant
Lipopeptide
TLR1/2 ligand
Immunotherapy
Vaccines
Online Access:http://link.springer.com/article/10.1186/s40425-019-0796-5

Internet

http://link.springer.com/article/10.1186/s40425-019-0796-5

Similar Items